This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters To the Editor

Reply to “Possible Impact of Dropout in a Study ofHigh-Dose Olanzapine and Prolactin Levels”

James L. Karagianis, MD, FRCPC Anton Baksh, MD, FRCPC

Published: August 16, 2004

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: While we agree that dropouts could potentially influence this type of study, in this particular study they did not. All patients were from the senior author’s (J.L.K.’s ) clinical practice, and no patient meeting the inclusion criteria dropped out. All patients had to be taking at least 20 mg/day of olanzapine for at least 4 months. Furthermore, any patient who would have dropped out prior to meeting inclusion criteria could not have been considered to be on high-dose, long-term treatment. This study was not intended to address the issue of prolactin elevation after low-dose or short-term treatment with olanzapine.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 65

Quick Links: Psychiatry

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...